BioCentury
ARTICLE | Finance

Advantage, Omicron

Moderna, BioNTech shares among gainers as investors bet on impact of new variant

November 30, 2021 2:50 AM UTC

Shares of companies developing countermeasures against COVID-19 have surged since Wednesday as investors bank on higher demand for vaccines and boosters in the near term, but the long-term effects of the Omicron variant on vaccine developers are unclear...